Courtney Bovee, MD
Ophthalmology · Tampa, FLNPI 1427346683
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $548,813 of the $795,544 with a category attached, or 69.0%. AbbVie accounts for 87.7% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $187,957, 4.7 times the $39,705 reported in 2019. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,556 payments — averaging $511.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$698K
- Glaukos Corporation$38K
- NEW World Medical,inc.$14K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$11K
- Harrow Eye, LLC$10K
- Sight Sciences, Inc.$10K
- plus $14K from 29 others
Across 7 payments — averaging $13,649 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$83K
- AbbVie$12K
What the payments were for
- Consulting fees$115,54615%
- Speaking & faculty fees$548,81369%
- Travel & lodging$87,24411%
- Food & beverage$43,5975%
- Education$1960%
- Gifts$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$626,221
- LUMIGAN$26,629
- Travoprost Intraocular Implant - iDose$21,808
- VYZULTA$13,960
- iDose$12,965
- Ahmed Glaucoma Valve$11,582
- Kahook Dual Blade$11,582
- VEVYE$9,416
- OMNI$7,609
- XEN GLAUCOMA TREATMENT SYSTEM$4,613
- COMBIGAN$2,844
- RADIUS$1,531
- Tecnis 1-piece IOL$1,036
- Tecnis 3-piece IOL$1,036
- Tecnis Symphony IOL$1,036
- Tecnis Symphony Toric IOL$1,036
- Streamline Surgical System$857
- OMNI(R) SURGICAL SYSTEM (US)$754
- Clearpath$727
- Streamline$727
How this compares
$795,544 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DurystaBimatoprost | 59 | $222,778 |
| LumiganBimatoprost | 345 | $177,798 |
| RocklatanNetarsudil Mesylat/Latanoprost | 257 | $106,382 |
| CombiganBrimonidine Tartrate/Timolol | 217 | $75,946 |
| RhopressaNetarsudil Mesylate | 191 | $67,169 |
| VyzultaLatanoprostene Bunod | 65 | $29,567 |
| Brimonidine Tartrate | 710 | $26,945 |
| Alphagan PBrimonidine Tartrate | 44 | $16,920 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,224 | $16,169 |
| Latanoprost | 1,500 | $16,043 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 112 | $13,477 |
| RestasisCyclosporine | 17 | $12,312 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $8,402 |
| Ketorolac Tromethamine | 272 | $8,324 |
| Acetazolamide | 97 | $7,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieDurysta, Lumigan, Combigan, Alphagan P, Restasis | $697,661 | $505,755682 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $489 | $173,550448 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $4,632 | $29,56765 claims |
| AlconSimbrinza | $1,804 | $8,40239 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $11,386 | $1,95813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Tampa
- Ivan SunerTampa$378K
- Pedram HamrahTampa$187K
- Thomas NewsomTampa$186K
- Don PerezTampa$178K
- Brian SzaboTampa$86K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.